103 related articles for article (PubMed ID: 27093726)
1. [Future Perspectives in Treatment of Ovarian Cancer].
Fujiwara K
Gan To Kagaku Ryoho; 2016 Feb; 43(2):174-5. PubMed ID: 27093726
[No Abstract] [Full Text] [Related]
2. New drugs in ovarian cancer.
Fleming GF
Clin Adv Hematol Oncol; 2015 Apr; 13(4):223-5. PubMed ID: 26352580
[No Abstract] [Full Text] [Related]
3. Immunotherapy for ovarian cancer: what are the targets of the future?
Adams SF; Benencia F
Future Oncol; 2015; 11(9):1293-6. PubMed ID: 25952776
[No Abstract] [Full Text] [Related]
4. Immunotherapy for ovarian cancer: recent advances and perspectives.
Zsiros E; Tanyi J; Balint K; Kandalaft LE
Curr Opin Oncol; 2014 Sep; 26(5):492-500. PubMed ID: 25036883
[TBL] [Abstract][Full Text] [Related]
5. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
[TBL] [Abstract][Full Text] [Related]
6. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer.
Adams M; Navabi H; Croston D; Coleman S; Tabi Z; Clayton A; Jasani B; Mason MD
Vaccine; 2005 Mar; 23(17-18):2374-8. PubMed ID: 15755631
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer: how can resistance to chemotherapy be tackled?
Karakashev S; Aird KM
Future Oncol; 2017 Dec; 13(30):2737-2739. PubMed ID: 29182383
[No Abstract] [Full Text] [Related]
8. The role of targeted therapy in ovarian cancer.
Banerjee S; Kaye S
Eur J Cancer; 2011 Sep; 47 Suppl 3():S116-30. PubMed ID: 21943965
[TBL] [Abstract][Full Text] [Related]
9. [Impact of molecular classification on clinical management of ovarian cancer].
Hasegawa K
Gan To Kagaku Ryoho; 2015 Feb; 42(2):166-8. PubMed ID: 25834913
[No Abstract] [Full Text] [Related]
10. Current concepts in the management of ovarian carcinoma.
Alberts DS
Ariz Med; 1975 Dec; 32(12):951-4. PubMed ID: 1217990
[No Abstract] [Full Text] [Related]
11. [II. Future perspectives of intraperitoneal chemotherapy for ovarian cancer].
Fujiwara K; Nagao S; Kurosaki A; Hasegawa K
Gan To Kagaku Ryoho; 2014 Feb; 41(2):184-7. PubMed ID: 24826385
[No Abstract] [Full Text] [Related]
12. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.
Banerjee S; Kaye SB
Clin Cancer Res; 2013 Mar; 19(5):961-8. PubMed ID: 23307860
[TBL] [Abstract][Full Text] [Related]
13. [Ovarian cancer: role of medical treatment].
Cappelaere P; Chauvergne J; Guerrin J
Bull Cancer; 1982; 69(3):284-91. PubMed ID: 7126897
[TBL] [Abstract][Full Text] [Related]
14. Investigational agents for epithelial ovarian cancer.
Muggia F; Kosloff R
Expert Rev Anticancer Ther; 2005 Oct; 5(5):855-68. PubMed ID: 16221055
[TBL] [Abstract][Full Text] [Related]
15. New perspectives in ovarian cancer treatment.
Schmid BC; Oehler MK
Maturitas; 2014 Feb; 77(2):128-36. PubMed ID: 24380827
[TBL] [Abstract][Full Text] [Related]
16. Preface.
Tainsky MA; Morris RT
Cancer Metastasis Rev; 2015 Mar; 34(1):3. PubMed ID: 25648358
[No Abstract] [Full Text] [Related]
17. [Treatment of ovarian clear cell carcinoma].
Mabuchi S; Takahashi R; Sasano T; Kuroda H; Kimura T
Gan To Kagaku Ryoho; 2015 Feb; 42(2):174-8. PubMed ID: 25834915
[No Abstract] [Full Text] [Related]
18. The changing landscape of therapeutic strategies for recurrent ovarian cancer.
Baumann KH; Wagner U; du Bois A
Future Oncol; 2012 Sep; 8(9):1135-47. PubMed ID: 23030488
[TBL] [Abstract][Full Text] [Related]
19. Anal fissures associated with targeted therapies in ovarian cancer.
Squires J
Clin J Oncol Nurs; 2009 Dec; 13(6):638-42. PubMed ID: 19948462
[TBL] [Abstract][Full Text] [Related]
20. [Combination of chemotherapy of malignant tumours, BCG vaccination with in particular of the ovaries (author's transl)].
Lédr J
Cesk Gynekol; 1974 Mar; 39(2):142-3. PubMed ID: 4452013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
